Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer

Background Triple-negative breast cancer (TNBC) corresponds to approximately 20% of all breast tumors, with a high propensity for metastasis and a poor prognosis. Because TNBC displays a high mutational load compared with other breast cancer types, a neoantigen-based immunotherapy strategy could be effective. One major bottleneck in the development of a neoantigen-based vaccine for TNBC is the selection of the best targets, that is, tumor-specific neoantigens which are presented at the surface of tumor cells and capable of eliciting robust immune responses. In this study, we aimed to set up a platform for identification and delivery of immunogenic neoantigens in a vaccine regimen for TNBC using oncolytic vaccinia virus (VV). Methods We used bioinformatic tools and cell-based assays to identify immunogenic neoantigens in TNBC patients’ samples, human and murine cell lines. Immunogenicity of the neoantigens was tested in vitro (human) and ex vivo (murine) in T-cell assays. To assess the efficacy of our regimen, we used a preclinical model of TNBC where we treated tumor-bearing mice with neoantigens together with oncolytic VV and evaluated the effect on induction of neoantigen-specific CD8+T cells, tumor growth and survival. Results We successfully identified immunogenic neoantigens and generated neoantigen-specific CD8+T cells capable of recognizing a human TNBC cell line expressing the mutated gene. Using a preclinical model of TNBC, we showed that our tumor-specific oncolytic VV was able to change the tumor microenvironment, attracting and maintaining mature cross-presenting CD8α+dendritic cells and effector T-cells. Moreover, when delivered in a prime/boost regimen together with oncolytic VV, long peptides encompassing neoantigens were able to induce neoantigen-specific CD8+T cells, slow tumor growth and increase survival. Conclusions Our study provides a promising approach for the development of neoantigen-based immunotherapies for TNBC. By identifying immunogenic neoantigens and developing a delivery system through tumor-specific oncolytic VV, we have demonstrated that neoantigen-based vaccines could be effective in inducing neoantigen-specific CD8+T cells response with significant impact on tumor growth. Further studies are needed to determine the safety and efficacy of this approach in clinical trials.

[1]  G. Freeman,et al.  A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies , 2022, Monoclonal antibodies in immunodiagnosis and immunotherapy.

[2]  R. Monasson,et al.  Neoantigen quality predicts immunoediting in survivors of pancreatic cancer , 2022, Nature.

[3]  D. Roy,et al.  Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination , 2021, Nature Communications.

[4]  S. H. van der Burg,et al.  Therapeutic cancer vaccines , 2021, Nature Reviews Cancer.

[5]  Christopher A. Miller,et al.  Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation , 2021, Genome Medicine.

[6]  W. Gillanders,et al.  Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy , 2021, Expert opinion on investigational drugs.

[7]  Michelle S. Miller,et al.  Bispecific antibodies targeting mutant RAS neoantigens , 2021, Science Immunology.

[8]  Peng Liu,et al.  A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer , 2021, Journal for ImmunoTherapy of Cancer.

[9]  A. Folgori,et al.  New viral vectors for infectious diseases and cancer. , 2020, Seminars in immunology.

[10]  C. Bessant,et al.  Characterization of four subtypes in morphologically normal tissue excised proximal and distal to breast cancer , 2020, npj Breast Cancer.

[11]  Chumeng Chen,et al.  Triggered Immune Response Induced by Antigenic Epitopes Covalently Linked with Immunoadjuvant-Pulsed Dendritic Cells as a Promising Cancer Vaccine , 2020, Journal of immunology research.

[12]  N. Lemoine,et al.  A new oncolytic Vaccinia virus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery , 2020, Journal for ImmunoTherapy of Cancer.

[13]  K. Peltonen,et al.  Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  N. Lemoine,et al.  Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent , 2017, Nature Communications.

[15]  Mithat Gönen,et al.  Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer , 2017, Nature.

[16]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[17]  Charles H. Yoon,et al.  An immunogenic personal neoantigen vaccine for patients with melanoma , 2017, Nature.

[18]  E. Jaffee,et al.  Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.

[19]  M. Mann,et al.  Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry , 2016, Nature Communications.

[20]  Lajos Pusztai,et al.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Walden,et al.  Diverse HLA-I Peptide Repertoires of the APC Lines MUTZ3-Derived Immature and Mature Dendritic Cells and THP1-Derived Macrophages , 2016, The Journal of Immunology.

[22]  Ton N. Schumacher,et al.  Targeting of cancer neoantigens with donor-derived T cell receptor repertoires , 2016, Science.

[23]  G. Jerusalem,et al.  Triple-negative breast cancer: treatment challenges and solutions , 2016, Breast cancer.

[24]  Morten Nielsen,et al.  Gapped sequence alignment using artificial neural networks: application to the MHC class I system , 2016, Bioinform..

[25]  J. Gartner,et al.  Immunogenicity of somatic mutations in human gastrointestinal cancers , 2015, Science.

[26]  A. Bunker,et al.  Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma , 2015, Oncoimmunology.

[27]  L. Molinero,et al.  Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) , 2015 .

[28]  P. Lollini,et al.  The Promise of Preventive Cancer Vaccines , 2015, Vaccines.

[29]  E. Mardis,et al.  A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells , 2015, Science.

[30]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[31]  Maxim N. Artyomov,et al.  Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.

[32]  Z. Modrušan,et al.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.

[33]  E. Ibrahim,et al.  The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis , 2014, Breast Cancer Research and Treatment.

[34]  The Uniprot Consortium,et al.  UniProt: a hub for protein information , 2014, Nucleic Acids Res..

[35]  I. Melero,et al.  Therapeutic vaccines for cancer: an overview of clinical trials , 2014, Nature Reviews Clinical Oncology.

[36]  P. Sharma,et al.  PD-L1 Expression in Triple-Negative Breast Cancer , 2014, Cancer Immunology Research.

[37]  Hannah Gilmore,et al.  MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer. , 2013, Human pathology.

[38]  Alessandro Sette,et al.  Properties of MHC Class I Presented Peptides That Enhance Immunogenicity , 2013, PLoS Comput. Biol..

[39]  B. Graham.  Advances in antiviral vaccine development , 2013, Immunological reviews.

[40]  M. Zody,et al.  ATHLATES: accurate typing of human leukocyte antigen through exome sequencing , 2013, Nucleic acids research.

[41]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[42]  J. Stagg,et al.  Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects , 2013, Therapeutic advances in medical oncology.

[43]  N. Lemoine,et al.  A Novel Therapeutic Regimen to Eradicate Established Solid Tumors with an Effective Induction of Tumor-Specific Immunity , 2012, Clinical Cancer Research.

[44]  Y. Welte,et al.  High Immunogenicity of the Human Leukocyte Antigen Peptidomes of Melanoma Tumor Cells* , 2012, The Journal of Biological Chemistry.

[45]  S. Guha,et al.  Cytokine network: new targeted therapy for pancreatic cancer. , 2012, Current pharmaceutical design.

[46]  Nicholas R. Lemoine,et al.  SNPnexus: a web server for functional annotation of novel and publicly known genetic variants (2012 update) , 2012, Nucleic Acids Res..

[47]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[48]  A. Lavasanifar,et al.  Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. , 2011, Advanced drug delivery reviews.

[49]  S. Sleijfer,et al.  Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes , 2011, Breast Cancer Research and Treatment.

[50]  N. Lemoine,et al.  Lister vaccine strain of vaccinia virus armed with the endostatin-angiostatin fusion gene: an oncolytic virus superior to dl1520 (ONYX-015) for human head and neck cancer. , 2011, Human gene therapy.

[51]  Leaf Huang,et al.  Cancer Immunotherapy and Nanomedicine , 2011, Pharmaceutical Research.

[52]  C. Hiley,et al.  Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours , 2009, Gene Therapy.

[53]  L. Carey,et al.  What is triple-negative breast cancer? , 2008, European journal of cancer.

[54]  M. Robert-Guroff.  Replicating and non-replicating viral vectors for vaccine development , 2007, Current Opinion in Biotechnology.

[55]  Robyn L Stanfield,et al.  How TCRs bind MHCs, peptides, and coreceptors. , 2006, Annual review of immunology.

[56]  G. Crooks,et al.  WebLogo: a sequence logo generator. , 2004, Genome research.

[57]  Peter Walden,et al.  Sequit: software for de novo peptide sequencing by matrix-assisted laser desorption/ionization post-source decay mass spectrometry. , 2004, Rapid communications in mass spectrometry : RCM.

[58]  Els Goulmy,et al.  Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. , 2003, Human immunology.

[59]  S. H. van der Burg,et al.  Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides1 , 2002, The Journal of Immunology.

[60]  T. D. Schneider,et al.  Sequence logos: a new way to display consensus sequences. , 1990, Nucleic acids research.

[61]  P. Sharma,et al.  PD-L 1 Expression in Triple-Negative Breast Cancer , 2014 .

[62]  O. Lund,et al.  NetMHCpan, a method for MHC class I binding prediction beyond humans , 2008, Immunogenetics.

[63]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.

[64]  O. Lund,et al.  Reliable prediction of T‐cell epitopes using neural networks with novel sequence representations , 2003, Protein science : a publication of the Protein Society.